Culture, Biotech Thomas Culman Culture, Biotech Thomas Culman

Introducing Biotech Unveiled

One of our guiding principals here at RApport and RA Capital is that we learn collaboratively; not just internally, but with the rest of our community as well. RApport is an important part of that (and as always, we encourage you to reach out with questions, comments, and op-ed ideas: rapport@racap.com), but RA University – in which many of our readers are already enrolled – is another. Recently, we’ve been rolling out RAU’s newest, on-demand course: Biotech Unveiled: Understanding the U.S. Biomedical Innovation Marketplace and its Global Role.

Read More
Biotech, Policy, Culture Peter Kolchinsky Biotech, Policy, Culture Peter Kolchinsky

Eroding tolerance: A wonder drug shows us the drug industry’s fundamental failure to communicate

Many people who dedicate their lives to discovering, developing, and making new, lifesaving drugs don’t understand the extent to which the drug industry has failed to communicate its value proposition to society and to inspire its customers to pay for that value. That is to say, when the public and even legislators representing our biotech innovation hubs focus on the price of a breakthrough drug without a sense of its value or how it came into being and insist that innovators should not only invent medicines but pay for them, too, that’s a self-inflicted wound. Vertex’s Trikafta, one of our industry’s greatest success stories, provides an example.

Read More